ZLAB Stock Recent News

Zai Lab collaborated with NovoCure on a study to treat non-small cell lung cancer. There were some concerns about the validity of the study.

SHANGHAI, China and CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company's senior management team will participate in the following investor conferences in June 2023:

Many Wall Street analysts still see an economic recovery playing out in China. President Biden recently said he expects relations with China to improve "very shortly.

Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET

Zai Lab will soon launch a handful of new medicines in China. It's also seeking approval for many of its therapies in the U.S. The company also has enough cash to survive even if some of its clinical trials fail.

Zai Lab Limited (NASDAQ:ZLAB ) Citi Biotech C-Suite Fireside Chat Series Conference Call February 14, 2023 11:00 AM ET Company Participants Josh Smiley - COO Conference Call Participants Yigal Nochomovitz - Citi Yigal Nochomovitz Okay, great. I'm Yigal Nochomovitz.

Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET

SHANGHAI and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company's senior management team will participate in the following investor conferences in February 2023:

Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company.